In patients with multiple sclerosis (MS), different interferon beta (IFN-β) formulations have been approved as disease modifying therapeutics for more than two decades and experience from historical clinical ADA testing is available (1–3). This evidence concerns the gene IFNB1 and multiple sclerosis.